Novel approach to the role of NMDA receptors in traumatic brain injury

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 4, 2014, Pages 567-573

  Shohami, Esther ^a   Biegon, Anat ^b,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Cognitive enhancer; D cycloserine; Glutamate receptors; Stroke

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOSERINE; DIZOCILPINE; GLUTAMATE RECEPTOR; GLYCINE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

ACUTE STRESS DISORDER; ARTICLE; BEHAVIOR; BRAIN DYSFUNCTION; BRAIN ISCHEMIA; COGNITION; DOSE RESPONSE; DRUG MEGADOSE; GLASGOW COMA SCALE; HIPPOCAMPUS; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OBSESSIVE COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMATOSENSORY STIMULATION; SPATIAL LEARNING; SYNAPSE; TRAUMATIC BRAIN INJURY; VISUAL DISCRIMINATION; ANIMAL; BRAIN; BRAIN INJURIES; DRUG EFFECTS; MENTAL DISORDERS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; BRAIN INJURIES; BRAIN ISCHEMIA; CYCLOSERINE; HUMANS; MENTAL DISORDERS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84904474376     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660196     Document Type: Article

References (83)

1. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984; 43: 1369-74.
2. Alessandri B, Landolt H, Langemann H, et al. Application of glutamate in the cortex of rats: a microdialysis study. Acta Neurochir Suppl 1996; 67: 6-12.
3. Baker AJ, Moulton RJ, MacMillan VH, Shedden PM. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J Neurosurg 1993; 79: 369-72.
4. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990; 13: 171-82.
5. Brown JI, Baker AJ, Konasiewicz SJ, Moulton RJ. Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans. J Neurotrauma 1998; 15: 253-63.
6. Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989; 244: 798-800.
7. Lynch DR, Dawson TM. Secondary mechanisms in neuronal trauma. Curr Opin Neurol 1994; 7: 510-6.
8. Beauchamp K, Mutlak H, Smith WR, Shohami E, Stahel PF. Pharmacology of traumatic brain injury-where is the golden bullet? Mol Med 2008; 14: 731-40.
9. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008; 7: 742-55.
10. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997; 49: S66-9.
11. Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31: 347-54.
12. Morris GF, Juul N, Marshall SB, Benedict B, Marshall LF. Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Executive Committee of the International Selfotel Trial. Neurosurgery 1998; 43: 1369-72.
13. Maas AI, Steyerberg EW, Murray GD, et al. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations. Neurosurgery 1999; 44: 1286-98.
14. Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma 2002; 19: 503-57.
15. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002; 1: 383-6.
16. Tolias CM, Bullock MR. Critical Appraisal of Neuroprotection Trials in Head Injury: What Have We Learned? NeuroRx 2004; 1: 71-9.
17. Hoyte L, Barber PA, Buchan AM, Hill MD. The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med 2004; 4(2): 131-6.
18. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006; 6: 53-60.
19. Shohami E, Biegon A. Controversial Findings on the Role of NMDA Receptors in Traumatic Brain Injury. In: Traumatic Brain and Spinal Cord Injury. Kossmann M, Maas R, eds. Cambridge University Press, UK 2011.
20. Davalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 1997; 28: 708-10.
21. Ginsberg MD. Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology 2008; 55: 363-89.
22. Obviagle B, Kidwell CS, Satrkama S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003; 3: 9-20.
23. Ogawa N, Haba K, Mizukawa K, et al. Loss of N-methyl-D-aspartate (NMDA) receptor binding in rat hippocampal areas at the chronic stage after transient forebrain ischemia: Histological and NMDA receptor binding studies. Neurochem Res 1991; 16(5): 519-24.
24. Grossman R, Shohami E, Alexandrovich A, et al. Increase in peripheral benzodiazepine receptors and loss of glutamate NMDA receptors in a mouse model of closed head injury: a quantitative autoradiographic study. Neuroimage 2003; 20: 1971-81.
25. Biegon A, Fry PA, Paden CM, et al. Delayed Activation, rather than inhibition, of glutamate NMDA receptors improves neurological outcome after closed head injury in mice. Proc Natl Acad Sci USA 2004; 101: 5117-22.
26. Dhawan J, Benveniste H, Nawrocky M, Smith SD, Biegon A. Transient focal ischemia results in persistent and widespread neuroinflammation and loss of glutamate NMDA receptors. NeuroImage 2010; 51: 599-605.
27. Temple MD, Hamm RJ. Chronic, post-injury administration of Dcycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Res 1996; 741: 246-51.
28. Madden DR. The structure and function of glutamate receptor ion channels. Nat Rev Neurosci 2002; 3(2): 91-101.
29. Albensi BC. The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and excitotoxicity. Curr Pharm Des 2007; 13(31): 3185-94.
30. Bowery NG. Glycine-binding sites and NMDA receptors in brain. Nature 1987; 326(6111): 338.
31. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325(6104): 529-31.
32. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988; 241(4867): 835-7.
33. Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50: 597-664.
34. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci 1996; 17(10): 348-355.
35. Morton RF, McKenna MH, Charles E. Studies on the absorption, diffusion, and excretion of cycloserine. Antibiot Annu 1956; 31: 169-72.
36. Rivas Salalzar JL. On cycloserine in the treatment of pulmonary tuberculosis and its use for postoerative protection. Scand J Respir Dis 1970; 71(suppl): 314-24.
37. Walker WC, Murdoch JM. Cycloserine in the trearment of pulmonary tuberculosis. A report on Toxicity. Tubercule (Lond) 1957; 38: 297.
38. Baron H, Epstein IG, Mulinos MG, Nair KG. Absorption, distribution, and excretion of cycloserine in man. Antibiot Annu 1955-6; 3: 136-40.
39. Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CAl. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001; 21: 891-7.
40. Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 1989; 98(1): 91-5.
41. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed Xenopus oocytes. Brain Res 1990; 510: 158-60.
42. Dravid SM, Burger PB, Prakash A, et al. Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci 2010; 30(7): 2741-54.
43. Pitkänen M, Sirviö J, Lahtinen H, Koivisto E, Riekkinen P. DCycloserine, a partial agonist at the glycine site, enhances the excitability of dentate granule cells in vivo in rats. Eur J Pharmacol 1994; 253(1-2): 125-9.
44. Baran H, Löscher W, Mevissen M. The glycine/NMDA receptor partial agonist D-cycloserine blocks kainate-induced seizures in rats. Comparison with MK-801 and diazepam. Brain Res 1994; 652(2): 195-200.
45. Lanthorn TH. D-Cycloserine: Agonist turned antagonist. Amino Acids 1994; 6: 247-60.
46. van Berckel BN, Lipsch C, Timp S, et al. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 1997; 16(5): 317-24.
47. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. Eur J Pharmacol 1994; 257: 7-12.
48. Yaka R, Biegon A, Grigoriadis N, et al. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J 2007; 21: 2033-41.
49. Liraz-Zaltsman S, Alexandrovich AG, Trembovler V, et al. Regional sensitivity to neuroinflammation: In vivo and in vitro studies. Synapse 2011; 65: 634-42.
50. Liraz-Zaltsman S, Alexandrovich AG, Shohami E, Biegon A. Dcycloserine improves cognitive deficits in a mouse model of neuroinflammation. J Mol Neurosci 2011; 45(Suppl 1): S75.
51. Adeleye A, Shohami E, Nachman D, et al. D-Cycloserine Improves Functional Outcome after Traumatic Brain Injury with Wide Therapeutic Window. Eur J Pharmacol 2010; 629: 25-30.
52. Bliss TV, Collingridge GL. A synaptic model of memory: longterm potentiation in the hippocampus. Nature 1993; 361: 31-9.
53. Malenka RC, Nicoll RA. Long-term potentiation--a decade of progress? Science 1999; 285: 1870-4.
54. Sanders MJ, Sick TJ, Perez-Pinzon MA, Dietrich WD, Green EJ. Chronic failure in the maintenance of long-term potentiation following fluid percussion injury in the rat. Brain Res 2000; 861: 69-76.
55. Sick TJ, Perez-Pinzon MA, Feng ZZ. Impaired expression of longterm potentiation in hippocampal slices 4 and 48 h following mild fluid-percussion brain injury in vivo. Brain Res 1998; 785: 287-92.
56. Schwarzbach E, Bonislawski DP, Xiong G, Cohen AS. Mechanisms underlying the inability to induce area CA1 LTP in the mouse after traumatic brain injury. Hippocampus 2006; 16: 541-50.
57. D'Ambrosio R, Maris DO, Grady MS, Winn HR, Janigro D. Selective loss of hippocampal long-term potentiation, but not depression, following fluid percussion injury. Brain Res 1998; 786: 64-79.
58. Sharma HS. Post-traumatic application of brain-derived neurotrophic factor and glia-derived neurotrophic factor on the rat spinal cord enhances neuroprotection and improves motor function. Acta Neurochir Suppl 2006; 96: 329-34.
59. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000; 14: 2919-37.
60. Korte M, Carroll P, Wolf E, et al. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92: 8856-60.
61. Yaka R, He DY, Phamluong K, Ron D. Pituitary adenylate cyclaseactivating polypeptide (PACAP(1-38)) enhances N-methyl-Daspartate receptor function and brain-derived neurotrophic factor expression via RACK1. J Biol Chem 2003; 278: 9630-8.
62. Fujihira T, Kanematsu S, Umino A, Yamamoto N, Nishikawa T. Selective increase in the extracellular D-serine contents by Dcycloserine in the rat medial frontal cortex. Neurochem Intl 2007; 51: 233-6.
63. Dhawan J, Benveniste H, Luo Z, et al. A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke. Fut Neurol 2011; 6: 823-34.
64. Thanos PK, Bermeo C, Wang GJ, Volkow ND. D-cycloserine facilitates extinction of cocaine self-administration in rats. Synapse 2011; 65(9): 938-44.
65. Nic Dhonnchadha BA, Szalay JJ, Achat-Mendes C, et al. Dcycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology 2010; 35(2): 357-67.
66. Levin ED, Slade S, Wells C, Petro A, Rose JE. D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response. Pharmacol Biochem Behav 2011; 98(2): 210-4.
67. Ledgerwood L, Richardson R, Cranney J. D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav Neurosci 2004; 118(3): 505-13.
68. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 2003; 117(2): 341-9.
69. Millecamps M, Centeno MV, Berra HH, et al. D-cycloserine reduces neuropathic pain behavior through limbic NMDAmediated circuitry. Pain 2007; 132(1-2): 108-23.
70. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000; 16(2 Suppl): S73-9.
71. Christensen D, Gautron M, Guilbaud G, Kayser V. Combined systemic administration of the glycine/NMDA receptor antagonist, (+)-HA966 and morphine attenuates pain-related behaviour in a rat model of trigeminal neuropathic pain. Pain 1999; 83(3): 433-40.
72. Tan-No K, Esashi A, Nakagawasai O, et al. Intrathecally administered D-cycloserine produces nociceptive behavior through the activation of N-methyl-D-aspartate receptor ion-channel complex acting on the glycine recognition site. J Pharmacol Sci 2007; 104(1): 39-45.
73. Schneider JS, Tinker JP, Van Velson M, Giardiniere M. Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res 2000; 860(1-2): 190-4.
74. Wang AL, Liou YM, Pawlak CR, Ho YJ. Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 2010; 208(1): 38-46.
75. Billard JM, Rouaud E. Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by D-cycloserine. Eur J Neurosci 2007; 25(8): 2260-8.
76. Matsumoto Y, Yoshida M, Watanabe S, Yamamoto T. Involvement of cholinergic and glutamatergic functions in working memory impairment induced by interleukin-1beta in rats. Eur J Pharmacol 2001; 430(2-3): 283-8.
77. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of Dcycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118-26.
78. Gottlieb JD, Cather C, Shanahan M, et al. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res 2011; 131: 69-74.
79. Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by d-cycloserine: theoretical and clinical implications. Learn Mem 2004; 11: 510-6.
80. Rothbaum BO. Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive compulsive disorder. Amer J Psyc 2008; 165(3): 293-6.
81. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-44.
82. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63: 298-304.
83. Chasson GS, Bhulmann U, Tolin DF, et al. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther 2010; 48: 675-9.